Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KAT2A/KAT2B degrader AUTX-703

An orally bioavailable, small molecule degrader of the histone acetyltransferases and transcriptional activators lysine acetyltransferase 2A (KAT2A) and its paralog lysine acetyltransferase 2B (KAT2B), with potential antineoplastic activity. Upon oral administration, KAT2A/KAT2B degrader AUTX-703 targets, binds to and selectively degrades KAT2A and KAT2B. This prevents the acetylation of non-histone substrates and transcription of certain genes, such as MYC. KAT2A/KAT2B degradation by AUTX-703 reverses the block in differentiation of certain cancer cells, promotes epithelial cell state differentiation towards a more terminally differentiated state, and inhibits proliferation in susceptible tumor cells. In addition, epithelial differentiation induced by AUTX-703 enhances expression of antigen presenting genes in certain tumor cells. KAT2A and KAT2B, epigenetic enzymes involved in normal human development, play a key role in tumor cell plasticity and in creating an altered, de-differentiated, and more proliferative cellular state in certain tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:KAT2A/B protein degrader AUTX-703
KAT2A/KAT2B protein degrader AUTX-703
Code name:AUTX 703
AUTX-703
AUTX703
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search